Eliane Schutte
Episode: 31
44 min
Eliane Schutte was appointed as Chief Executive Officer at Xeltis in 2018. During her time as CEO, the Company has strengthened and expanded its strategy across vascular and valve applications and closed more than €70 million of funding, including strategic license transactions. Under her leadership, Xeltis began its pivotal trials to obtain market approvals. She initially joined Xeltis in 2015 as Chief Development Officer, leading the clinical trial program, product development strategy and regulatory. Eliane has extensive expertise in global product development and regulatory affairs, with over 25 years in the medtech and biotech industries. Prior to Xeltis, she was Vice President for Global Product Development in peri-operative care at The Medicines Company, Chief Development Officer at Dutch-US biotech start-up Profibrix and Vice President for Regulatory Affairs and EU Operations at IsoTis Orthobiologics. Eliane was included in the list of The Top 50 Healthcare Technology CEOs by the Healthcare Technology Report in 2021 and 2022.
Eliane Schutte was appointed as Chief Executive Officer at Xeltis in 2018. During her time as CEO, the Company has strengthened and expanded its strategy across vascular and valve applications and closed more than €70 million of funding, including strategic license transactions. Under her leadership, Xeltis began its pivotal trials to obtain market approvals. She initially joined Xeltis in 2015 as Chief Development Officer, leading the clinical trial program, product development strategy and regulatory. Eliane has extensive expertise in global product development and regulatory affairs, with over 25 years in the medtech and biotech industries. Prior to Xeltis, she was Vice President for Global Product Development in peri-operative care at The Medicines Company, Chief Development Officer at Dutch-US biotech start-up Profibrix and Vice President for Regulatory Affairs and EU Operations at IsoTis Orthobiologics. Eliane was included in the list of The Top 50 Healthcare Technology CEOs by the Healthcare Technology Report in 2021 and 2022.
0:00/1:34
Klaas Poelstra en Laura Heitman
Episode: 67
50 min
Klaas Poelstra en Laura Heitman zijn resp. voorzitter en vice-voorzitter van de FIGON en praten met Henk Jan Out over hoe zij deze belangrijke samenwerking op wetenschappelijk gebied vormgeven.
Klaas Poelstra en Laura Heitman zijn resp. voorzitter en vice-voorzitter van de FIGON en praten met Henk Jan Out over hoe zij deze belangrijke samenwerking op wetenschappelijk gebied vormgeven.
Marc Kaptein
Episode: 64
49 min
Tijdens de coronacrisis kreeg hij landelijke bekendheid als medisch directeur van Pfizer die uitleg gaf over vaccinaties. Daarvoor had Marc Kaptein al een carrière achter de rug bij Organon, Eli Lilly en MyTomorrows. Momenteel is hij director external affairs bij Pfizer Nederland. Over zijn werkzaamheden praat hij met Henk Jan Out in de nieuwste podcast.
Tijdens de coronacrisis kreeg hij landelijke bekendheid als medisch directeur van Pfizer die uitleg gaf over vaccinaties. Daarvoor had Marc Kaptein al een carrière achter de rug bij Organon, Eli Lilly en MyTomorrows. Momenteel is hij director external affairs bij Pfizer Nederland. Over zijn werkzaamheden praat hij met Henk Jan Out in de nieuwste podcast.
Martine van Vugt
Episode: 63
50 min
Martine van Vugt is Executive VP en Chief Strategy Officer van Genmab, een toonaangevend biotechbedrijf met een marktwaarde van circa 20 miljard euro.
Martine van Vugt is Executive VP en Chief Strategy Officer van Genmab, een toonaangevend biotechbedrijf met een marktwaarde van circa 20 miljard euro.
Load More Podcast